Novo Nordisk’s Chinese Patent Shield and Teen Trial Win Create a Two-Fronted Story
Novo Nordisk faces a paradox: Chinese regulatory delays protect $1B semaglutide sales, while oral semaglutide targets teens and…
Browsing Tag